Neutropenia (Low White Blood Cell Count) Clinical Trial
Official title:
A Randomized Open-label, Multiple-dose, Crossover Study Evaluatig The Pharmacodynamics And Pharmacokinetics Of Filgrastim Hospira Compared To Us-approved Neupogen (Registered) Following Subcutaneous Administration To Healthy Volunteers
| Verified date | July 2016 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is
approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds
of white blood cells (WBC) known as neutrophils. This type of white cell is important in
fighting infections. A low neutrophil count is known as neutropenia. Both drugs work by
increasing the number of neutrophils that are produced in the body.
This is important for patients who have low neutrophils due to chemotherapy, other
treatments such as bone marrow transplant or certain other conditions with symptoms/problems
related to low neutrophil counts. The main aim of the study is to test how Filgrastim
Hospira works in the body compared to Neupogen®.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | June 2016 |
| Est. primary completion date | June 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: A subject will be eligible for study participation if all of the following criteria are met at Screening: 1. Provides written informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB) prior to any study related activities 2. Healthy male or female volunteers between 18 and 65 years of age (both inclusive) 3. Body mass index (BMI) between 19 and 30 kg/m2, inclusive, and body weight of not < 50 kg or > 100 kg 4. Non smoker (defined as a subject who has not smoked and has not used nicotine containing products for at least 3 months prior to study drug administration and has a negative urine screen for cotinine) at Screening 5. Female subjects of childbearing potential and male subjects and their partners of childbearing potential, agree to pregnancy prevention throughout the duration of the study (through the Final Visit). Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study. Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. While the best way to avoid pregnancy is to abstain from sexual activity, adequate forms of contraception to be used include oral contraception, depot contraception, intrauterine device (IUD), and barrier contraceptive methods, such as condoms and barrier creams/contraceptive jellies, and spermicidals. Subjects and their partners who can become pregnant must use contraception while on study drug from admission to the Final Visit. Male subjects must also refrain from donating sperm from admission to the Final Visit 6. Agrees to abstain from alcohol consumption throughout duration of the study and has a negative urine for alcohol at Screening Exclusion Criteria: A subject will NOT be eligible for study participation if any of the following criteria are met at Screening: 1. Any active systemic or immunologic disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic infection, or lactation 2. Hematologic laboratory abnormalities including leukocytosis (defined as total leukocytes > 11,000/µL), leukopenia (defined as total leukocytes < 4000/µL), or neutropenia (defined as absolute neutrophil count [ANC] < 1500/µL) or thrombocytopenia (defined as platelet count of < 150/µL) 3. Clinically significant, as judged by the Investigator, vital sign, chest X-ray, or 12-lead electrocardiogram (ECG) abnormality 4. History of biological growth factor exposure, including but not limited to filgrastim and other granulocyte-colony stimulating factors (G-CSFs) in the context of treatment, prophylaxis, peripheral blood stem cell mobilization, or previous investigational study setting 5. Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic reaction to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, other granulocyte colony-stimulating factors or any component of the product: Subjects with the rare heredity problem of fructose intolerance are excluded due to the excipient sorbitol 6. History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or pneumonia, sickle cell disorders, chronic neutropenia, thrombocytopenia, or vasculitis |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| United States | SeaView Research, Inc. | Miami | Florida |
| United States | SeaView Research, Inc. | Miami | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer | Hospira, is now a wholly owned subsidiary of Pfizer |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The Area under the effect curve for CD34+ (AUECCD34+) | prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period | No | |
| Primary | Maximum observed value for CD34+ (CD34+max) | prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period | No | |
| Primary | Area under the serum filgrastim concentration versus time curve from time zero to 24 hours (AUC0-24) | prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period | No | |
| Primary | Maximum serum filgrastim concentration (Cmax) following study drug administration on Day 5 | prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period | No | |
| Secondary | Time to maximum CD34+ count (Tmax[CD34+]) | prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period | No | |
| Secondary | The concentration prior to dose on Day 5 (Ctrough) | prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period. | No | |
| Secondary | Time to maximum serum filgrastim concentration (Tmax) | prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period. | No | |
| Secondary | Elimination half-life (t1/2) from serum filgrastim concentrations following dose administration on Day 5 | prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period. | No |